Phase 3 Data on Brilaroxazine for Schizophrenia with Larry Ereshefsky, PharmD
In an interview with HCPLive, Larry Ereshefsky, PharmD, discussed the phase 3 RECOVER trial assessing brilaroxazine at 50 mg and 15 mg for acute schziophrenia.
In an interview with HCPLive, Larry Ereshefsky, PharmD, discussed the phase 3 RECOVER trial assessing brilaroxazine at 50 mg and 15 mg for acute schziophrenia.
Practice Network, a new initiative, aims to help smaller hospitals implement AI tools in local settings where adoption is currently stymied.
This essay describes the author’s experience of improved patient care and collaboration the day the the electronic medical records system went down.
This 2024 Recommendation Statement from the US Preventive Services Task Force recommends biennial screening mammography for women aged 40 to 74 years (B recommendation) and…
This cohort study examines prespecified health outcomes after vaccination with an ancestral monovalent COVID-19 vaccine in US children aged 6 months to 17 years.
This survey study examines preferences and willingness to pay for facility-based vs home-based postacute care among patients and caregivers.
Can AI/machine learning-driven digital phenotyping facilitate global personalized medicine? In this Q&A, Vikram Patel, MBBS, PhD, the Paul Farmer Professor and chair of the Department…
JAMA Health Forum Editor John Ayanian, MD, MPP, speaks with Kelsey M. Owsley, PhD, of the University of Arkansas, and Sayeh Nikay, PhD, MPH, of…
The news that Sarah Benn has been suspended from the medical register sends a bleak message to climate concerned younger doctors, writes Alexander Mafi Doctors…
New studies point to potential for greater reliance on objective imaging biomarkers for accurate diagnosis of multiple sclerosis.
Continuity of care—seeing the same GP over time—reduces the need for emergency care and increases longevity in patients.1 It leads to better patient satisfaction and…